AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 7 |
Market Cap | 458.16M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.08 |
PE Ratio (ttm) | -4.16 |
Forward PE | n/a |
Analyst | Buy |
Ask | 9.74 |
Volume | 670,354 |
Avg. Volume (20D) | 624,552 |
Open | 9.00 |
Previous Close | 8.92 |
Day's Range | 8.42 - 9.13 |
52-Week Range | 4.09 - 17.58 |
Beta | undefined |
About STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...
Analyst Forecast
According to 8 analyst ratings, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 131.21% from the latest price.
Next Earnings Release
Analysts project revenue of $2.97M, reflecting a 6.03% YoY growth and earnings per share of -0.56, making a -6.67% decrease YoY.